| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T75797 | ||||
| Target Name | Prostaglandin F2-alpha receptor | ||||
| Target Type | Successful |
||||
| Drug Potency against Target | Latanoprost | Drug Info | Ki = 98 nM | [552404] | |
| LAROPIPRANT | Drug Info | Ki = 9991 nM | [528672] | ||
| Travoprost | Drug Info | EC50 = 17.5~37 nM | [552320] | ||
| References | |||||
| Ref 552404 | Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003 Dec;19(6):501-15. | ||||
| Ref 528672 | J Med Chem. 2007 Feb 22;50(4):794-806.Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). | ||||
| Ref 552320 | Real-time intracellular Ca2+ mobilization by travoprost acid, bimatoprost, unoprostone, and other analogs via endogenous mouse, rat, and cloned human FP prostaglandin receptors. J Pharmacol Exp Ther. 2003 Jan;304(1):238-45. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.